{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:16:45Z","timestamp":1783469805536,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.seminhematol.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T15:35:16Z","timestamp":1722699316000},"page":"348-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes"],"prefix":"10.1053","volume":"61","author":[{"given":"Mary M.","family":"Czech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gea-Banacloche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0002","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ejh.12883","article-title":"Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine","volume":"99","author":"Radsak","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.blre.2018.10.002","article-title":"Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0004","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.039","article-title":"Infections in myelodysplastic syndrome in relation to stage and therapy","volume":"10","author":"Leone","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ACI.0000000000000126","article-title":"GATA2 deficiency","volume":"15","author":"Hsu","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.07.004_bib0006","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040808","article-title":"Infectious complications in patients with myelodysplastic syndromes: a report from the dusseldorf MDS registry","volume":"16","author":"Kasprzak","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bjh.18542","article-title":"Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry","volume":"200","author":"Madry","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.107000","article-title":"Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes","volume":"124","author":"Pianelli","year":"2023","journal-title":"Leuk Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.clml.2019.09.610","article-title":"Combination of frailty status and comorbidity score improves the stratification of survival in patients with myelodysplastic syndrome owing to good predictive capability for infection-related mortality","volume":"19","author":"Sakatoku","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.004_bib0011","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0012","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.004_bib0013","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/10428194.2020.1751841","article-title":"A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure","volume":"61","author":"Duong","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0014","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(17)30228-4","article-title":"Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial","volume":"5","author":"Mittelman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"28","key":"10.1053\/j.seminhematol.2024.07.004_bib0015","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.22.02699","article-title":"Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.004_bib0016","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1080\/10428194.2019.1576873","article-title":"A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure","volume":"60","author":"Swaminathan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.004_bib0017","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/bjh.14792","article-title":"Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy","volume":"178","author":"Fenaux","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.004_bib0018","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(18)30016-4","article-title":"Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial","volume":"5","author":"Kantarjian","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0019","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-017-2366-2","article-title":"Iron and infection","volume":"107","author":"Ganz","year":"2018","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.004_bib0020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2009.017244","article-title":"Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Koreth","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0021","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2018.02.005","article-title":"Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: relation to infections and possible benefit of iron chelation therapy","volume":"67","author":"Wong","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.13067","article-title":"Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: results from the National Registry of the Italian Drug Agency","volume":"101","author":"Arcioni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.004_bib0023","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1080\/10428194.2017.1421758","article-title":"Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q)\u201d results of a phase 3 trial","volume":"59","author":"Almeida","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clml.2018.12.012","article-title":"Clinical benefit-risk profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase III trial","volume":"19","author":"Garcia-Manero","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.20.01691","article-title":"Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin","volume":"39","author":"List","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-22-1457","article-title":"Lenalidomide and eltrombopag for treatment of low- or intermediate-risk myelodysplastic syndrome: result of a phase II clinical trial","volume":"29","author":"Gonzalez-Lugo","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41408-022-00765-8","article-title":"Bonadies N. management of patients with lower-risk myelodysplastic syndromes","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0028","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00277-018-3458-7","article-title":"Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts","volume":"97","author":"Baek","year":"2018","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0029","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1111\/cas.14653","article-title":"No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: a retrospective study of Nagasaki","volume":"111","author":"Toriyama","year":"2020","journal-title":"Cancer Sci"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.07.004_bib0030","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.004_bib0031","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/cas.13739","article-title":"Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial","volume":"109","author":"Morita","year":"2018","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.004_bib0032","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/10428194.2017.1366998","article-title":"Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia","volume":"59","author":"Sanchez-Garcia","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1053\/j.seminhematol.2024.07.004_bib0033","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1002\/cncr.34492","article-title":"Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: a phase 2, multicenter, randomized trial","volume":"128","author":"Park","year":"2022","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221127547","article-title":"Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD","volume":"13","author":"Vilorio-Marques","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.004_bib0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clml.2019.01.002","article-title":"Predictive model for infection risk in myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia patients treated with azacitidine; azacitidine infection risk model: the polish adult leukemia group study","volume":"19","author":"Madry","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.004_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ajco.12835","article-title":"Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: results from a multicenter, single-arm, open-label phase 2 study","volume":"14","author":"Du","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0037","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/ejh.14012","article-title":"Treatment in patients with acute myeloid leukemia\/high-risk myelodysplastic syndrome with hypomethylating agents: day-hospital management compared to home care setting","volume":"111","author":"Trape","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.701690","article-title":"Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis","volume":"12","author":"Ma","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.004_bib0039","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: a network meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0040","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.928454","article-title":"Evaluation of reduced-dose decitabine and azacitidine for treating myelodysplastic syndromes: a retrospective study","volume":"27","author":"Hu","year":"2021","journal-title":"Med Sci Monit"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.004_bib0041","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.7150\/jca.56207","article-title":"Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study","volume":"12","author":"Ye","year":"2021","journal-title":"J Cancer"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bcmd.2019.03.010","article-title":"Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \u226560\u202fyears and has lower toxicities: Comparison with low-dose chemotherapy","volume":"77","author":"Ye","year":"2019","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0043","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-022-00698-2","article-title":"G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial","volume":"12","author":"Stopka","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.004_bib0044","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hon.2710","article-title":"Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment","volume":"38","author":"Latagliata","year":"2020","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0046","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.25808","article-title":"Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents","volume":"95","author":"Kim","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0047","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ejh.13631","article-title":"Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"107","author":"Tey","year":"2021","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.004_bib0048","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0049","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/16078454.2021.1956182","article-title":"Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'","volume":"26","author":"Madry","year":"2021","journal-title":"Hematology"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.004_bib0050","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00277-019-03724-9","article-title":"Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice","volume":"98","author":"Scalzulli","year":"2019","journal-title":"Ann Hematol"},{"issue":"30","key":"10.1053\/j.seminhematol.2024.07.004_bib0051","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study)","volume":"39","author":"Kroger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.07.004_bib0052","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","article-title":"Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0053","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.18389","article-title":"Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)","volume":"199","author":"Sternberg","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.07.004_bib0054","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/10428194.2021.1872068","article-title":"A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes","volume":"62","author":"Huselton","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2018.201152","article-title":"Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia","volume":"104","author":"Kenealy","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.004_bib0056","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41375-022-01537-w","article-title":"Randomized phase II study of azacitidine +\/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)","volume":"36","author":"Rasmussen","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.004_bib0057","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.18193","article-title":"A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's \"pick a winner\" trial, with the impact of somatic mutations","volume":"198","author":"Ades","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0058","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.07.004_bib0059","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1158\/1078-0432.CCR-22-1810","article-title":"Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine","volume":"28","author":"O'Connell","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.07.004_bib0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.07.004_bib0061","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1007\/s00432-019-03031-w","article-title":"The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine","volume":"145","author":"Xiu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0062","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0063","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.30383","article-title":"Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.07.004_bib0064","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0065","unstructured":"Tucker N, Sava J. FDA approves luspatercept-aamt for upfront treatment of anemia in lower-risk MDS. FDA. 2023."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0066","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"10399","key":"10.1053\/j.seminhematol.2024.07.004_bib0067","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.07.004_bib0068","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","article-title":"FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0069","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0070","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2024.07.004_bib0071","doi-asserted-by":"crossref","first-page":"e18588ff","DOI":"10.1097\/01.HS9.0000967600.18588.ff","article-title":"S172: phase 1\/2 study of oral decitabine\/cedazuridine in combination with venetoclax in treatment-na\u00efve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia","volume":"7","author":"Bataller","year":"2023","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0072","unstructured":"Mauro G, Rosa K. FDA approves ivosidenib for relapsed\/refractory IDH1-mutant MDS. FDA. 2023."},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0073","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.004_bib0074","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/cncr.35251","article-title":"Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Dinh","year":"2024","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2024.07.004_bib0075","doi-asserted-by":"crossref","first-page":"e75740ab","DOI":"10.1097\/01.HS9.0000969800.75740.ab","article-title":"P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED\/REFRACTORY MYELODYSPLASTIC SYNDROME","volume":"7","author":"Dinardo","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.07.004_bib0076","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia."},{"issue":"16","key":"10.1053\/j.seminhematol.2024.07.004_bib0077","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2024.07.004_bib0078","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-21-4525","article-title":"FDA approval summary: oral azacitidine for continued treatment of adults with acute myeloid leukemia unable to complete intensive curative therapy","volume":"28","author":"Jen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0079","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.leukres.2018.08.001","article-title":"CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia","volume":"72","author":"Garcia-Manero","year":"2018","journal-title":"Leuk Res"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.07.004_bib0080","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0081","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.07.004_bib0082","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0083","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10423","key":"10.1053\/j.seminhematol.2024.07.004_bib0084","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"51","key":"10.1053\/j.seminhematol.2024.07.004_bib0086","doi-asserted-by":"crossref","first-page":"88904","DOI":"10.18632\/oncotarget.21492","article-title":"Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes","volume":"8","author":"Asayama","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.07.004_bib0087","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0088","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0089","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0090","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.07.004_bib0091","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.07.004_bib0092","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-017-3091-x","article-title":"The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment","volume":"96","author":"Lorenzana","year":"2017","journal-title":"Ann Hematol"},{"issue":"30","key":"10.1053\/j.seminhematol.2024.07.004_bib0093","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0094","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2024.07.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966882","article-title":"Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents","volume":"11","author":"Kang","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.07.004_bib0096","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0097","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.07.004_bib0098","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the european organization for research and treatment of cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.07.004_bib0099","doi-asserted-by":"crossref","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases: results from a subgroup analysis of a multicenter national registry","volume":"10","author":"Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.07.004_bib0100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1200\/OP.24.00107","article-title":"Vaccination of adults with cancer: ASCO guideline clinical insights","volume":"20","author":"Kamboj","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.07.004_bib0101","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:52:44Z","timestamp":1734025964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0037196324000854"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.07.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}